MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

NCT05007106 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

613

Enrollment

INDUSTRY

Sponsor class

Conditions

Uterine Cervical Neoplasms
Endometrial Neoplasms
Squamous Cell Carcinoma of Head and Neck
Gallbladder Neoplasms
Cholangiocarcinoma
Esophageal Neoplasms
Triple Negative Breast Neoplasms
Hepatocellular Carcinoma
Urinary Bladder Neoplasms
Ovarian Neoplasms
Stomach Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab/Vibostolimab Co-Formulation
BIOLOGICAL: Pembrolizumab
DRUG: Lenvatinib
DRUG: 5-Fluorouracil
DRUG: Cisplatin
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Carboplatin
DRUG: Docetaxel
DRUG: Bevacizumab
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Merck Sharp & Dohme LLC